Solvias Acquires Cergentis

Eurofins Acquires Genetic Testing Service JSC (Gentis) in Vietnam

February 9, 2022

Healthcare Services

Eurofins Scientific, via its subsidiary Eurofins Clinical Testing Lux Sarl, has acquired Genetic Testing Service JSC (Gentis), a leading provider of specialised genetic and clinical testing in Vietnam. The acquisition expands Eurofins' clinical diagnostics footprint in Southeast Asia and adds Gentis' genetic testing capabilities and customer relationships with hospitals and consumers.

Eurofins (via Eurofins Clinical Testing Lux) Acquires Genetic Testing Service JSC (Gentis) in Vietnam

February 9, 2022

Healthcare Services

Eurofins Scientific, through its subsidiary Eurofins Clinical Testing Lux Sarl, has acquired Genetic Testing Service JSC (Gentis), a market leader in specialised genetic testing in Vietnam. The deal expands Eurofins' footprint in Southeast Asia and strengthens its clinical genetics and advanced molecular diagnostics capabilities in the region.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Solvias Acquires Chemic Laboratories to Establish U.S. Laboratory Presence

June 17, 2021

Healthcare Services

Solvias has acquired Canton, Massachusetts-based Chemic Laboratories, Inc., giving the Swiss analytical testing and contract research company a U.S. foothold and complementary laboratory testing capabilities. Chemic's co-founders will join Solvias' leadership and continue to run U.S. operations; financial terms were not disclosed.

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.

Charles River Laboratories Acquires Cognate BioServices

February 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Cognate BioServices for approximately $875 million in cash, expanding Charles River's capabilities into the high-growth cell and gene therapy CDMO sector. Cognate, headquartered in Memphis, Tennessee with over 500 employees, will provide Charles River integrated cell and gene therapy development, testing, and CGMP manufacturing capabilities; the deal was expected to close by end of Q1 2021.